Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type
N Apisarnthanarax, GS Wood, SR Stevens… - Archives of …, 2012 - jamanetwork.com
Objectives To evaluate the toxic effects and maximum tolerated dose of topical carmustine
[1, 3-bis (2-chloroethyl)-1-nitrosourea] following intravenous O6-benzylguanine in the
treatment of cutaneous T-cell lymphoma (CTCL), and to determine pharmacodynamics of O6-
alkylguanine DNA alkyltransferase activity in treated CTCL lesions. Design Open-label,
dose-escalation, phase I trial. Setting Dermatology outpatient clinic and clinical research unit
at a university teaching hospital. Patients A total of 21 adult patients (11 male, 10 female) …
[1, 3-bis (2-chloroethyl)-1-nitrosourea] following intravenous O6-benzylguanine in the
treatment of cutaneous T-cell lymphoma (CTCL), and to determine pharmacodynamics of O6-
alkylguanine DNA alkyltransferase activity in treated CTCL lesions. Design Open-label,
dose-escalation, phase I trial. Setting Dermatology outpatient clinic and clinical research unit
at a university teaching hospital. Patients A total of 21 adult patients (11 male, 10 female) …
